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a bs t r ac t
BACKGROUND

Sentinel-lymph-node biopsy is associated with increased melanoma-specific survival (i.e.,
survival until death from melanoma) among patients with node-positive intermediatethickness melanomas (1.2 to 3.5 mm). The value of completion lymph-node dissection for
patients with sentinel-node metastases is not clear.
METHODS

In an international trial, we randomly assigned patients with sentinel-node metastases detected
by means of standard pathological assessment or a multimarker molecular assay to immediate
completion lymph-node dissection (dissection group) or nodal observation with ultrasonography (observation group). The primary end point was melanoma-specific survival. Secondary end
points included disease-free survival and the cumulative rate of nonsentinel-node metastasis.

The authors’ full names, academic de‑
grees, and affiliations are listed in the
Appendix. Address reprint requests to Dr.
Faries at 11818 Wilshire Blvd., Suite 200,
Los Angeles, CA 90025, or at mfaries@
theangelesclinic.org.
N Engl J Med 2017;376:2211-22.
DOI: 10.1056/NEJMoa1613210
Copyright © 2017 Massachusetts Medical Society.

RESULTS

Immediate completion lymph-node dissection was not associated with increased melanomaspecific survival among 1934 patients with data that could be evaluated in an intention-totreat analysis or among 1755 patients in the per-protocol analysis. In the per-protocol analysis, the mean (±SE) 3-year rate of melanoma-specific survival was similar in the dissection
group and the observation group (86±1.3% and 86±1.2%, respectively; P = 0.42 by the logrank test) at a median follow-up of 43 months. The rate of disease-free survival was slightly
higher in the dissection group than in the observation group (68±1.7% and 63±1.7%, respectively; P = 0.05 by the log-rank test) at 3 years, based on an increased rate of disease control
in the regional nodes at 3 years (92±1.0% vs. 77±1.5%; P<0.001 by the log-rank test); these
results must be interpreted with caution. Nonsentinel-node metastases, identified in 11.5%
of the patients in the dissection group, were a strong, independent prognostic factor for
recurrence (hazard ratio, 1.78; P = 0.005). Lymphedema was observed in 24.1% of the patients in the dissection group and in 6.3% of those in the observation group.
CONCLUSIONS

Immediate completion lymph-node dissection increased the rate of regional disease control
and provided prognostic information but did not increase melanoma-specific survival
among patients with melanoma and sentinel-node metastases. (Funded by the National
Cancer Institute and others; MSLT-II ClinicalTrials.gov number, NCT00297895.)
n engl j med 376;23
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entinel-lymph-node biopsy is a standard procedure in the care of appropriately
selected patients with melanoma. The first
Multicenter Selective Lymphadenectomy Trial
(MSLT-I) confirmed the value of early nodal
evaluation and treatment.1-3 This prospective,
international, randomized trial showed that the
pathologic status of the sentinel node or nodes
was the most important prognostic factor and
that patients who underwent sentinel-node biopsy
had fewer recurrences of melanoma than patients who underwent wide excision and nodal
observation. Among patients with intermediatethickness melanomas (defined as 1.2 to 3.5 mm)
and nodal metastases, early surgical treatment,
guided by sentinel-node biopsy, was associated
with increased melanoma-specific survival (survival until death from melanoma). These results
provide support for the recommendation by several professional organizations that staging by
means of sentinel-node biopsy should be performed when appropriate.4-7
Currently, immediate completion lymph-node
dissection (removal of the remaining regional
lymph nodes after sentinel-node excision) is usually recommended for patients with sentinel-node
metastases. However, prospective evidence of the
efficacy of completion lymph-node dissection is
lacking, and the procedure carries a risk of adverse events.8 Results of retrospective evaluations
of the usefulness of completion lymph-node dissection are inconclusive.9-11 Available data from
one prospective study do not suggest a benefit
from immediate dissection, but this study is not
sufficiently powered to rule out a clinically significant benefit.12 In addition, in most patients,
nodal disease is limited to the sentinel lymph
node or nodes and is removed by means of biopsy. Conversely, patients with even microscopic
involvement of nonsentinel nodes have an overall poorer prognosis and outcomes that are
similar to those in patients with clinically apparent nodal disease.13,14
In the second Multicenter Selective Lymphadenectomy Trial (MSLT-II), we evaluated the usefulness of completion lymph-node dissection in
patients with melanoma and sentinel lymphnode metastases as compared with observation
with frequent nodal ultrasonography and dissection only in patients in whom clinically detected
nodal recurrence had developed.

n engl j med 376;23
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Me thods
Trial Design and Oversight

MSLT-II, an international, multicenter, randomized, phase 3 trial to evaluate the usefulness of
completion lymph-node dissection in patients
with melanoma and sentinel-node metastases,
consisted of a screening phase in which patients
were enrolled before sentinel-node biopsy and a
randomization phase in which completion lymphnode dissection was compared with observation
and nodal ultrasonography (Fig. 1). The trial was
conducted at 63 centers.
MSLT-II was designed by the MSLT-II executive committee with input from the pathology
and ultrasonography oversight committees (see
the Supplementary Appendix, available with the
full text of this article at NEJM.org). Data were
collected prospectively on paper and later on
Web-based case-report forms. The authors vouch
for the accuracy and completeness of the data
and analyses reported and for the fidelity of the
trial to the protocol, available at NEJM.org.
Nodal metastasis was determined by means
of standard pathological assessment (including
immunohistochemical tests performed according
to institutional protocols) or by means of a previously described quantitative reverse-transcriptase–polymerase-chain-reaction (RT-PCR) assay
during the screening phase.15 Patients had to
have undergone randomization and completion
lymph-node dissection within 140 days after diagnostic biopsy.
The randomization phase involved enrollment
of patients who had undergone screening and
had pathologically or molecularly positive sentinelnode metastases and patients who had not undergone screening in whom sentinel-node metastases were detected by means of pathological
assessment. In the randomization phase, fewer
patients with RT-PCR–positive findings than
anticipated were enrolled. In 2012, the data and
safety monitoring board determined that such
patients should no longer undergo randomization,
since attainment of sufficient power to evaluate
Figure 1 (facing page). Trial Design, Enrollment,
and Outcomes.
RT-PCR denotes reverse-transcriptase polymerase
chain reaction.
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3531 Patients were screened and enrolled

251 Were ineligible
91 Had no data or did not undergo
sentinel-node biopsy

608 Were sentinel-node positive

2581 Were sentinel-node negative

835 Were not qualified for RT-PCR
673 Were not at RT-PCR center or joined
study after RT-PCR had ended
162 Had inadequate paraffin sample
231 Declined
randomization

1339 Were RT-PCR negative
407 Were RT-PCR positive
181 Declined
randomization

377 Underwent randomization

226 Underwent randomization

1939 Underwent randomization
1934 Had data that could be evaluated

1431 Were directly enrolled in
randomization phase
95 Were ineligible
1336 Underwent randomization

971 Were assigned to completion
lymph-node dissection
824 Underwent dissection
140 Declined dissection
3 Did not undergo dissection for unknown reason
4 Were ineligible

968 Were assigned to nodal
observation
931 Underwent observation
29 Declined observation
7 Did not undergo observation for unknown
reason
1 Was ineligible

626 Were included in follow-up
23 Completed follow-up
200 Died
83 Withdrew
30 Were lost to follow-up
3 Had other disease
2 Had protocol violation

664 Were included
in follow-up
6 col
27 Completed405
follow-up
pt
197 Died
34 Withdrew
42 Were lost to follow-up
2 Had other disease
1 Had protocol violation

967 Were included in intention-to-treat analysis
824 Were included in per-protocol analysis

967 Were included in intention-to-treat analysis
931 Were included in per-protocol analysis
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a therapeutic effect in that group was not feasible. The data and safety monitoring board recommended continued follow-up of these patients to
assess outcomes.
At the third interim analysis, the data and
safety monitoring board determined that detection of a significant survival difference between
the trial groups was unlikely and recommended
that the current primary end-point data be released. Intention-to-treat and per-protocol analyses of the outcome variables showed similar
results. Results of per-protocol analyses are
reported in this article, since they are likely to
be the most clinically pertinent. The intention-totreat data for the primary end point (melanomaspecific survival) are provided in Figure S1 in the
Supplementary Appendix.
Patients

Eligible patients who provided written informed
consent were randomly assigned to undergo completion lymph-node dissection or nodal observation. These patients were 18 to 75 years of age
and had clinically localized cutaneous melanoma,
an Eastern Cooperative Oncology Group performance status of 0 or 1 (on a 5-point scale, with
0 indicating an absence of disability and higher
numbers indicating greater disability), a non–
melanoma-related life expectancy of 10 years or
more, and a tumor-positive sentinel node. The
trial was opened before the universal application
of registration. The trial opened in December
2004 and was registered at Clinicaltrials.gov on
February 27, 2006. At the time of registration,
119 patients had been enrolled in the trial.
Randomization was performed in a 1:1 ratio
with the use of a permuted-block design, which
was stratified according to Breslow thickness,
ulceration, method of metastasis detection (standard pathological assessment or RT-PCR assay),
and enrollment at an MSLT-I center. Patients who
were assigned to the observation group were
monitored by means of clinical examination every
4 months during the first 2 years, every 6 months
during years 3 through 5, and then annually.
Nodal ultrasonographic assessment of the sentinel-node basin occurred at each visit for the first
5 years; findings were considered to be abnormal on the basis of a length:depth ratio of less
than 2, a hypoechoic center, an absence of hilar
vessels, or focal nodularity with increased vascu-

2214
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larity. Follow-up of the dissection group involved
the same schedule, but without protocol-mandated nodal ultrasonography.
Statistical Analysis

For the primary end point, melanoma-specific
survival, we used the log-rank test to compare
the rates among patients in the dissection group
and the observation group in the intention-totreat population. Secondary end points included
overall survival, disease-free survival, survival
without recurrence of regional nodal metastases,
distant metastasis–free survival, and the extent
of nodal involvement. Time zero was the time of
randomization. Melanoma-specific survival was
determined at the time of melanoma-related
death. Disease-free survival was the time to any
recurrence. Survival without nodal recurrence
was the time to recurrence within the draining
nodal basin. For survival, comparisons between
the two groups were performed by means of the
log-rank test for univariable testing and Cox regression for adjusted comparisons. Nodal recurrence occurred in a draining regional basin, local
and in-transit recurrence occurred between the
primary site and the regional basin, and distant
recurrence occurred beyond the regional basin.
We estimated that with a total sample of 1925
patients, the trial would have a power of 83% to
detect a between-group difference of 5 percentage points in melanoma-specific survival. All tests
were two-tailed. Power was reassessed by the
data and safety monitoring board before closure
of enrollment to ensure that an adequate sample
size had been obtained. The cumulative rate of
nonsentinel-node metastases was determined by
clinical follow-up in the observation group and
according to total in-basin nodal recurrence or
nonsentinel-node metastasis on immediate completion lymph-node dissection in the dissection
group.
Data were summarized with means and standard deviations, medians and ranges, or both in
the intention-to-treat and per-protocol analyses.
Chi-square and Wilcoxon rank-sum tests were
used to compare results for patients in the dissection group who actually underwent completion lymph-node dissection (these patients were
included in the per-protocol and intention-totreat analyses) with results for those who did not
undergo the assigned completion lymph-node dis-
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section (these patients were included only in the
intention-to-treat analysis). Survival curves were
computed with the use of the Kaplan–Meier
method and stratified according to group alone
or according to group and method of metastasis
detection (pathological assessment vs. RT-PCR).
Cox proportional-hazards regression models were
constructed separately for the two groups; these
models included demographic factors, trial stratification factors, and nonsentinel-node metastasis at the time of completion lymph-node dissection. Subgroup analyses included subgroups that
were defined according to the patients’ sex and
age, the Breslow thickness, the location and
number of positive nodes, and the presence or
absence of ulceration. Cox proportional-hazards
regression was used to estimate the subgroupspecific hazard ratios.

R e sult s
Patients

From December 2004 through March 2014, a
total of 3531 patients were enrolled in the
screening phase and 1939 patients underwent
randomization (Fig. 1). Demographic and pathologic features of the dissection and observation
groups were similar (Table 1, and Table S1 in the
Supplementary Appendix). A greater proportion
of patients assigned to completion lymph-node
dissection than to observation declined their assigned treatment. However, the per-protocol cohorts were similar with respect to prognostic
factors (Table 1).
In the dissection group, 143 patients were excluded from the per-protocol analysis. Of those
patients, 140 declined the assigned treatment.
Patients who were excluded from the per-protocol analysis were more likely than patients who
were not excluded to have never smoked, to have
nonulcerated primary tumors, and to have an
RT-PCR–positive sentinel node (Table S2 in the
Supplementary Appendix). The sentinel-node tumor burden in both groups was low; the median
diameter of the largest tumor deposit was 0.61
mm in the dissection group and 0.67 mm in the
observation group.
Survival Rates

At 3 years of follow-up, there was no significant
difference in the mean (±SE) rate of melanoma-

n engl j med 376;23

specific survival between the dissection group
and the observation group in the per-protocol
analysis (86±1.3% and 86±1.2%, respectively;
P = 0.42 by the log-rank test) (Fig. 2A) or the intention-to-treat analyses (Fig. S1 in the Supplementary
Appendix). In addition, there was no significant
between-group difference in melanoma-specific
survival after adjustment for other prognostic
factors (hazard ratio for death, 1.08; 95% confidence interval [CI], 0.88 to 1.34; P = 0.42).
An analysis with available follow-up data suggested that an RT-PCR–positive sentinel node did
not have an effect on survival that was as negative as the effect anticipated in the statistical
design of the trial, so the results from the two
groups are also reported separately here and in
the remaining analyses (Fig. 2B). The results of
an analysis of both groups together are shown in
Figure S2 in the Supplementary Appendix. A subgroup analysis, including an analysis based on
sentinel-node tumor burden, did not reveal any
subgroups that derived a significant melanomaspecific survival benefit from completion lymphnode dissection (Fig. S3 in the Supplementary
Appendix).
At 3 years of follow-up, the rate of diseasefree survival was slightly higher in the dissection
group than in the observation group (68±1.7%
and 63±1.7%, respectively; P = 0.05 by the log-rank
test) (Fig. 3A, and Fig. S2A in the Supplementary
Appendix), although the results of secondary
outcome analyses must be viewed cautiously given
the lack of significance for the primary end
point. This difference in disease-free survival
appears to result from a reduction in the rate of
nodal recurrence after completion lymph-node
dissection (Fig. 3B, and Fig. S2B in the Supplementary Appendix). This corresponds to an increase in the rate of disease control in the regional
nodes at 3 years (92±1.0% in the dissection
group vs. 77±1.5% in the observation group,
P<0.001 by the log-rank test). After adjustment,
the rate of nodal recurrence among patients
with sentinel-node metastases detected by means
of pathological assessment was 69% lower in the
dissection group than in the observation group
(hazard ratio, 0.31; 95% CI, 0.24 to 0.41; P<0.001).
No significant between-group difference in distant metastasis–free survival was detected (adjusted hazard ratio, 1.10; 95% CI, 0.92 to 1.31;
P = 0.31) (Fig. 3C, and Fig. S2C in the Supplemen-
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Table 1. Baseline Characteristics of the Patients in the Per-Protocol Analysis.*
Dissection
(N = 824)

Characteristic

Observation
(N = 931)

Sex — no. (%)
Female

346 (42.0)

382 (41.0)

Male

478 (58.0)

549 (59.0)

52.5±12.9

53.2±13.6

53.7 (18–76)

54.9 (19–76)

Never

463/803 (57.7)

522/907 (57.6)

Former

193/803 (24.0)

227/907 (25.0)

Current

147/803 (18.3)

158/907 (17.4)

Age — yr
Mean
Median (range)
Smoking status — no./total no. (%)†

Breslow thickness
Mean — mm

2.76±2.34

2.70±2.11

2.10 (0.34–28.0)

2.10 (0.35–30.0)

<1.50 mm — no. (%)

237 (28.8)

257 (27.6)

1.50–3.50 mm — no. (%)

404 (49.0)

462 (49.6)

>3.50 mm — no. (%)

183 (22.2)

212 (22.8)

Arm or leg

327 (39.7)

382 (41.0)

Head or neck

113 (13.7)

128 (13.7)

Trunk

384 (46.6)

421 (45.2)

Absent

508 (61.7)

578 (62.1)

Present

316 (38.3)

353 (37.9)

Median (range) — mm

Primary site — no. (%)

Ulceration — no. (%)

No. of positive sentinel lymph nodes — no. of
patients (%)
0, RT-PCR–positive

80 (9.7)

111 (11.9)

1

596 (72.3)

643 (69.1)

2

121 (14.7)

162 (17.4)

3

18 (2.2)

10 (1.1)

>3

9 (1.1)

5 (0.5)

Diameter of sentinel-lymph-node metastasis — mm‡
Mean

1.07

1.11

Median

0.61

0.67

0.27–1.32

0.23–1.38

Interquartile range
Size of sentinel-lymph-node metastasis — no. of
patients/total no. (%)
<0.1 mm

45/566 (8.0)

65/623 (10.4)

0.1–1.0 mm

333/566 (58.8)

343/623 (55.1)

>1.0 mm

188/566 (33.2)

215/623 (34.5)

66/814 (8.1)

60/922 (6.5)

Received adjuvant therapy — no./total no. (%)§

*	Plus–minus values are means ±SD. There were no significant between-group differences in the characteristics listed here.
Percentages may not total 100 because of rounding. RT-PCR denotes reverse-transcriptase polymerase chain reaction.
†	Data were missing for 21 patients in the dissection group and 24 patients in the observation group.
‡	The sentinel-node metastasis burden, the longest diameter of the largest tumor deposit, was not available for 178 patients
in the dissection group and 197 patients in the observation group.
§	Data were not available for 10 patients in the dissection group and 9 patients in the observation group.
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Probability of Melanoma-Specific
Survival

A

Prognostic Factors

Potential prognostic factors affecting melanomaspecific survival were examined. Since the pathologic status of nonsentinel nodes was unknown
in the observation group, the two groups of the
trial were considered separately. In the entire
trial (including patients with positive RT-PCR
results), Breslow thickness and the number of
sentinel nodes that were positive on pathological
assessment (0 vs. >0) were significant prognostic factors in both groups, and male sex was a
significant prognostic factor in the observation
group (Table S3 in the Supplementary Appendix). However, since the RT-PCR group appeared
to be prognostically distinct, an analysis was
also performed that included only patients with
sentinel nodes that were positive on pathological
assessment (Table 2). In the observation group,
male sex was no longer a significant prognostic
factor, and it remained nonsignificant in the dissection group. Breslow thickness was a significant prognostic factor in both groups, and the
pathologic status of nonsentinel nodes was a
significant prognostic factor in the dissection
group (hazard ratio for death, 1.78; P = 0.005).
The number of involved sentinel nodes was not
a significant prognostic factor.
Among patients who underwent immediate
completion lymph-node dissection, nonsentinelnode metastases were detected on pathological
assessment in 11.5%, and over time, with nodal
recurrences in that group, the percentage of
patients in whom nonsentinel-node metastases
were detected increased to an actuarial rate of
17.9% at 3 years and 19.9% at 5 years (Fig. 3D).
In the observation group, the percentage of
patients in whom ultrasonographic or physical
examination revealed involved nonsentinel nodes
increased to 22.9% at 3 years and 26.1% at 5 years,
exceeding the rate in the dissection group at both
time points (P = 0.02 and P = 0.005, respectively).
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tary Appendix). Types of initial recurrence are
listed in Table S4 in the Supplementary Appendix.
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Figure 2. Melanoma-Specific Survival, According to Trial Group and Method of Detection of Metastasis.
Panel A shows melanoma-specific survival according to trial group (com‑
pletion lymph-node dissection or observation) in the per-protocol analysis.
Panel B shows melanoma-specific survival according to the method of de‑
tection of sentinel-node metastasis (RT-PCR or pathological assessment).
Subgroup 1 comprised patients in the dissection group with pathologically
detected metastases; subgroup 2, patients in the observation group with
pathologically detected metastases; subgroup 3, those in the dissection
group with RT-PCR–detected metastases; and subgroup 4, those in the ob‑
servation group with RT-PCR–detected metastases. P values were calculat‑
ed with the use of log-rank tests.

had had lymphedema (P<0.001). Among the patients who had lymphedema, this condition was
Adverse events were more common among pa- mild in 64%, moderate in 33%, and severe in 3%.
tients after completion lymph-node dissection
than among patients in the observation group.
Discussion
At the most recent follow-up on April 30, 2016,
a total of 24.1% of the patients in the dissection The management of regional lymph nodes has
group and 6.3% of those in the observation group long been controversial in the treatment of many
Adverse Events
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Figure 3. Disease-free Survival, Survival without Nodal Recurrence, and Distant Metastasis–free Survival, According to Trial Group,
and the Cumulative Rate of Nonsentinel-Node Metastasis.
Panel A shows disease-free survival, Panel B shows survival without nodal recurrence, and Panel C shows distant metastasis–free survival
according to trial group (completion lymph-node dissection or observation). Subgroup 1 comprised patients in the dissection group
with pathologically detected metastases; subgroup 2, patients in the observation group with pathologically detected metastases; sub‑
group 3, those in the dissection group with RT-PCR–detected metastases; and subgroup 4, those in the observation group with RT-PCR–
detected metastases. Panel D shows the cumulative rate of nonsentinel-node metastasis among patients in the dissection group who
had positive findings on pathological assessment or nodal recurrence and among patients in the observation group who had nodal re‑
currence. P values were calculated with the use of log-rank tests.

solid tumors, particularly melanoma.16 The
MSLT-I confirmed the staging value of sentinelnode biopsy and showed a therapeutic advantage
of early treatment of nodal metastases among
2218
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patients with intermediate-thickness melanoma.3
The findings of that trial provided support for
the use of sentinel-node biopsy, which is now
recommended in the guidelines of most national
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Table 2. Hazard Ratios for Melanoma-Related Death, According to Multivariable Prognostic Factors.*
Prognostic Factor

Dissection

Observation

Hazard Ratio
(95% CI)

P Value

Hazard Ratio
(95% CI)

P Value

Sex: male vs. female

1.13 (0.80–1.59)

0.50

1.41 (0.98–2.05)

0.07

Age, per 1-yr increase

1.00 (0.99–1.01)

0.93

1.01 (0.99–1.02)

0.15

0.07

2.46 (1.34–4.53)

Breslow thickness
<1.50 mm†

1.00

1.00

1.50–3.50 mm

1.64 (0.96–2.79)

>3.50 mm

3.82 (2.19–6.66)

<0.001

4.32 (2.31–8.09)

<0.001

1.97 (1.40–2.77)

<0.001

2.17 (1.55–3.05)

<0.001

Ulceration: present vs. absent

0.004

Site of melanoma
Arm or leg†

1.00

1.00

Head or neck

0.81 (0.44–1.48)

0.49

1.60 (0.96–2.66)

0.07

Trunk

1.26 (0.89–1.77)

0.19

1.05 (0.74–1.49)

0.80

No. of positive sentinel nodes
1†

1.00

2

1.08 (0.71–1.62)

0.73

1.27 (0.87–1.84)

0.21

≥3

1.17 (0.61–2.24)

0.64

2.01 (0.82–4.95)

0.13

1.78 (1.19–2.67)

0.005

NA

Nonsentinel nodes: positive vs. negative

1.00

*	Patients with positive findings on RT-PCR were excluded from this analysis. NA denotes not applicable.
†	This group served as the reference group.

and professional organizations for the treatment
of melanoma.4-7
However, in patients with sentinel-node metastases, the value of completion lymph-node dissection remains controversial. Since most such
patients have all nodal metastases removed by
means of the sentinel-node biopsy procedure,
they cannot derive additional therapeutic value
from completion lymph-node dissection. Even
microscopic nonsentinel-node metastases portend a markedly worse prognosis, similar to that
of patients with bulky, clinically diagnosed metastases,13,14 than the prognosis in patients with
metastases that are limited to the sentinel lymph
nodes. Patients with nonsentinel-node metastasis may be unlikely to benefit from early dissection. Finally, completion lymph-node dissection
is associated with higher morbidity than sentinelnode biopsy alone, so an appraisal of the value
of the procedure is important.
Previous data regarding this clinical question
have been inconclusive. Retrospective series have
produced varied results and are subject to a conn engl j med 376;23

siderable risk of selection bias.9-11 The findings
of one prospective study were similar to those in
our trial, but its size (483 patients underwent
randomization) and most recent follow-up left
enough statistical uncertainty to preclude definitive conclusions.12 MSLT-II, in which 1939 patients underwent randomization with a median
follow-up of 43 months, provided sufficient data
to resolve the central question: no significant
survival benefit was imparted by immediate completion lymph-node dissection among patients
with sentinel-node metastases. However, completion lymph-node dissection did provide other
potential value for patients with melanoma,
including improved staging and an increased
rate of regional disease control.
Most patients in the trial population had a
low-volume nodal tumor burden. Indeed, some
patients had only molecular indications of melanoma in the sentinel node, determined by means
of RT-PCR. Those patients had outcomes that
were not as poor as those in retrospective studies
using the same assay.15,17 However, any variance
nejm.org
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from pretrial event-rate estimates is unlikely to
have affected the overall result, since the RT-PCR–
positive group constituted only 12% of the randomized study population. Furthermore, the number of patients with pathologically detected
metastases actually exceeded the number in the
statistical plan. Patients with a larger sentinelnode tumor burden are more likely than patients
with a smaller burden to have nonsentinel-node
metastases, and the small number of patients
with a larger sentinel-node tumor burden in this
trial limits statistical confidence for those patients specifically. It may be possible to use an
estimation of the risk of nonsentinel-node metastases based on sentinel-node tumor burden and
primary tumor characteristics to help identify
patients who may benefit from completion lymphnode dissection.18-20 However, a subgroup evaluation of patients with a greater disease burden
(maximal tumor diameter >1 mm) did not indicate that a benefit from completion lymph-node
dissection was more likely in high-risk groups
than in low-risk groups.
The current trial confirms that the pathologic status of nonsentinel nodes has independent prognostic value, whereas the number of
involved sentinel nodes was not significantly
related to melanoma-specific survival. Although
this finding is somewhat counterintuitive, it
echoes retrospective data from multiple institutions.13,14 This confirmation in a prospective
trial of the large effect of nonsentinel node
status on prognosis reaffirms its staging value.
A lack of this information may impede the most
appropriate risk stratification and selection of
adjuvant therapy for patients who do not undergo completion lymph-node dissection.
Immediate completion lymph-node dissection
reduced the rate of regional nodal recurrence by
nearly 70%, leading to a small but significant
decrease in the overall risk of recurrence. Since
no significant difference between the groups
was noted in the primary end point, differences
with respect to the secondary end points must
be interpreted with caution. A nonsignificant
difference in distant metastasis–free survival
was noted at late time points, but as of this writing, events at those time points have been few,
and additional follow-up is necessary. Our trial
was unable to determine the safety of avoiding
completion lymph-node dissection in patients
who are unable to undergo frequent follow-up
2220
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evaluations or in patients who receive treatment
at institutions that are not able to perform
nodal ultrasonography.
The advantages of immediate completion
lymph-node dissection are tempered by the complications of the procedure. As of this writing,
lymphedema has been observed in 24% of the
patients in the dissection group and 6% of the
patients in the observation group. As expected,
there were significantly more complications
among patients who underwent completion
lymph-node dissection than among those who
did not, although the adverse events associated
with the surgical procedure were often transient.
Although a complete assessment and comparison of lymphedema with other complications
would require additional follow-up, we think
that the decreased overall number of dissections
among patients in the observation group will
translate into decreased complications.
The lack of a survival advantage associated
with immediate completion lymph-node dissection in this trial contrasts with the results of the
MSLT-I. In that trial, patients with nodal disease
and intermediate-thickness melanomas had better outcomes with immediate surgery than with
delayed surgery. The lack of a survival benefit
with completion lymph-node dissection in patients
in MSLT-II suggests that any increase in survival
with early surgery occurred among patients with
disease that was limited to the sentinel node.
Patients with nonsentinel-node metastases may
still undergo salvage treatment with completion
lymph-node dissection, but the timing of that
intervention does not appear to be critical.
Early completion lymph-node dissection did
not increase survival in the MSLT-II population.
It is possible that this was due to dilution of a
therapeutic effect, since approximately three
quarters of the population did not have melanoma in nonsentinel nodes. A comparison of
results in patients with nonsentinel-node metastases in this trial, similar to the latent subgroup
analysis in MSLT-I, might address this possibility, but it would be difficult to accomplish.21
First, in this population with a low disease
burden and with the most recent follow-up, additional nodal recurrences are expected. Second,
even at the most recent follow-up, an imbalance
in the observed proportion of patients with nonsentinel node–positive disease was noted, with
an excess in the observation group. This may be
nejm.org
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due to small nonsentinel-node metastases that
were not detected on standard pathological examination. Intensive evaluation of nonsentinel
nodes with the use of immunohistochemical
tests indicates that the frequency of these occult
metastases in completion lymph-node dissection
specimens is very similar to that of excess nodal
recurrences (8 to 10%).18
Overall, some value may be derived from immediate completion lymph-node dissection with
regard to staging and an increased rate of regional disease control. However, this value comes
at the cost of increased complications.
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